e-Therapeutics plc Issue of Equity (7708C)
October 21 2020 - 4:06AM
UK Regulatory
TIDMETX
RNS Number : 7708C
e-Therapeutics plc
21 October 2020
e-therapeutics plc
("e-therapeutics" or the "Company")
Issue of equity
Oxford, UK, 21 October 2020 - e-therapeutics plc (AIM: ETX,
"e-therapeutics" or the "Company") announce that on 20 October 2020
an application has been made for the issue of 1,683,333 new
ordinary shares of 0.1p each (the "New Ordinary Shares") in order
to satisfy the exercise of share options by former Non-Executive
Directors. The grant of the share options was announced on 11
February 2020.
An application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur on 26 October 2020. The New Ordinary Shares will
rank pari passu in all respects with the Company's existing
ordinary shares in issue.
Following Admission, the total number of ordinary shares in the
Company with voting rights in issue will be 420,740,129. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
-Ends-
For further information, please contact:
e-therapeutics plc
Ali Mortazavi, Executive Chairman and Tel: +44 (0)1993 883
CEO 125
www.etherapeutics.co.uk
Numis Securities Limited Tel: +44 (0) 207 260
Freddie Barnfield/Duncan Monteith (Nominated 1000
Adviser) www.numis.com
James Black (Corporate Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a
powerful computer-based approach to drug discovery, founded on its
industry-leading expertise in network biology to fully capture
disease complexity. The Company combines network science, machine
learning, artificial intelligence, statistics and access to big
data with expertise in drug discovery and development to transform
the search for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that
enables the rapid screening of millions of compounds and the
identification of small sub-sets that are enriched for highly
active hits. Its proprietary platform also has novel applications
in functional genomics, being able to analyse complex genetic
datasets, provide a deep understanding of pathological mechanisms
and distil actionable insights for the discovery of novel drugs,
biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic
drug discovery platform both in house and with partners, including
Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical
company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEFELSAFESSESS
(END) Dow Jones Newswires
October 21, 2020 04:06 ET (08:06 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024